{"nctId":"NCT00125164","briefTitle":"Prepubertal Children With Growth Failure Associated With Primary Insulin-Like Growth Factor-1 (IGF-1) Deficiency","startDateStruct":{"date":"2004-03"},"conditions":["Growth Disorders","Insulin-Like Growth Factor-1 Deficiency"],"count":137,"armGroups":[{"label":"Untreated","type":"NO_INTERVENTION","interventionNames":[]},{"label":"40 μg/kg BID (twice daily dosing)","type":"EXPERIMENTAL","interventionNames":["Drug: rhIGF-1 (mecasermin, Tercica, Inc.)"]},{"label":"80 μg/kg BID (twice daily dosing)","type":"EXPERIMENTAL","interventionNames":["Drug: rhIGF-1 (mecasermin, Tercica, Inc.)"]},{"label":"120 μg/kg BID (twice daily dosing)","type":"EXPERIMENTAL","interventionNames":["Drug: rhIGF-1 (mecasermin, Tercica, Inc.)"]}],"interventions":[{"name":"rhIGF-1 (mecasermin, Tercica, Inc.)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Chronological age ≥ 3 and chronological or bone age less than or equal to 11 years inclusive in girls;\n* Chronological age ≥ 3 and chronological or bone age less than or equal to 12 years inclusive for boys\n* Prepubertal\n* Height SD score of \\< -2\n* IGF-1 SD score of \\< -2\n\nExclusion Criteria:\n\n* Prior treatment with rhGH, rhIGF-1, or other growth-influencing medications\n* Growth failure associated with other identifiable causes (e.g., syndromes, chromosomal abnormality)\n* Chronic illness such as diabetes, cystic fibrosis, etc.","healthyVolunteers":false,"sex":"ALL","minimumAge":"3 Years","maximumAge":"12 Years","stdAges":["CHILD"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Height Velocity During the First Year - Intent to Treat (ITT)Population","description":"Height to be measured standing without shoes as the average of three measurements by the same observer using identical technique with a Harpenden or other wall mounted stadiometer. Reposition subject between each measurement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.2","spread":"1.0"},{"groupId":"OG002","value":"6.9","spread":"1.0"},{"groupId":"OG003","value":"7.7","spread":"1.5"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Height Standard Deviation (SD) Score at One Year - ITT Population","description":"Height to be measured standing without shoes as the average of three measurements by the same observer using identical technique with a Harpenden or other wall mounted stadiometer. Reposition subject between each measurement. Please note that Standard Deviation (SD) Score is a term used in growth studies. The SD Score is calculated as the patient value minus the mean divided by the standard deviation. The mean and the standard deviation vary depending on the age and sex of the child.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.02","spread":"0.24"},{"groupId":"OG002","value":"0.38","spread":"0.17"},{"groupId":"OG003","value":"0.48","spread":"0.32"}]}]}]},{"type":"SECONDARY","title":"Changes in Bone Age From Baseline to One Year","description":"Plain X-rays of the left hand and wrist exposed for bone age appraisal. The films are sent to a central facility for standardized evaluation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":"0.3"},{"groupId":"OG002","value":"1.1","spread":"0.4"},{"groupId":"OG003","value":"1.2","spread":"0.5"}]}]}]},{"type":"SECONDARY","title":"Percent Changes From Baseline in Serum Concentrations of IGF-1 at One Year","description":"Blood sample was collected while subject is in a fasting state for measuring the level of IGF-1 in the growth factor panel.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64","spread":"120"},{"groupId":"OG002","value":"227","spread":"220"},{"groupId":"OG003","value":"266","spread":"215"}]}]}]},{"type":"SECONDARY","title":"Percent Changes From Baseline in Serum Concentrations of IGF-2 at One Year","description":"Blood sample was collected for measuring the level of IGF-2 in the growth factor panel.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":"28"},{"groupId":"OG002","value":"-38","spread":"37"},{"groupId":"OG003","value":"-37","spread":"32"}]}]}]},{"type":"SECONDARY","title":"Percent Changes From Baseline in Serum Concentrations of Insulin-like Growth Factor Binding Protein-2 (IGFBP-2) at One Year","description":"Blood sample was collected for measuring the level of insulin-like growth factor binding protein-2 (IGFBP-2) in the growth factor panel.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-16","spread":"26"},{"groupId":"OG002","value":"58","spread":"84"},{"groupId":"OG003","value":"61","spread":"79"}]}]}]},{"type":"SECONDARY","title":"Percent Changes From Baseline in Serum Concentrations of Insulin-like Growth Factor Binding Protein-3 (IGFBP-3) at One Year","description":"Blood sample was collected while subject is in a fasting state for measuring the level of IGFBP-3 in the growth factor panel.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":"33"},{"groupId":"OG002","value":"-19","spread":"22"},{"groupId":"OG003","value":"-19","spread":"28"}]}]}]},{"type":"SECONDARY","title":"IGF Generation Test: Change of Serum IGF-1 After 7 Days Exposure to Recombinant Human Growth Hormone (rhGH)","description":"Blood drawn at Study Day 1, followed by 7 days of rhGH daily dosing at 0.05 mg/kg of body weight. Additional blood draw at Study Day 7.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40","spread":"49"},{"groupId":"OG002","value":"53","spread":"49"},{"groupId":"OG003","value":"48","spread":"43"}]}]}]},{"type":"SECONDARY","title":"IGF Generation Test: Change of Serum IGFBP-3 After 7 Days Exposure to Recombinant Human Growth Hormone (rhGH)","description":"Blood drawn at Study Day 1, followed by 7 days of rhGH daily dosing at 0.05 mg/kg of body weight. Additional blood draw at Study Day 7.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"744","spread":"459"},{"groupId":"OG002","value":"800","spread":"1095"},{"groupId":"OG003","value":"681","spread":"568"}]}]}]},{"type":"POST_HOC","title":"Height Velocity During the First Year for Subjects - Completers","description":"Height to be measured standing without shoes as the average of three measurements by the same observer using identical technique with a Harpenden or other wall mounted stadiometer. Reposition subject between each measurement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.2","spread":"1.0"},{"groupId":"OG002","value":"7.0","spread":"1.0"},{"groupId":"OG003","value":"7.9","spread":"1.4"}]}]}]},{"type":"POST_HOC","title":"Change From Baseline in Height Standard Deviation (SD) Score at One Year - Completers","description":"Height to be measured standing without shoes as the average of three measurements by the same observer using identical technique with a Harpenden or other wall mounted stadiometer. Reposition subject between each measurement. Please note that Standard Deviation (SD) Score is a term used in growth studies. The SD Score is calculated as the patient value minus the mean divided by the standard deviation. The mean and the standard deviation vary depending on the age and sex of the child.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.02","spread":"0.24"},{"groupId":"OG002","value":"0.39","spread":"0.17"},{"groupId":"OG003","value":"0.53","spread":"0.30"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":25},"commonTop":["Headache","Upper respiratory tract infection","Cough","Nasopharyngitis","Hypoglycemia"]}}}